structure of Sorafenib

Sorafenib

CAS No.: 100012-18-8
M. Wt: 909
M. Fa: C44H36MnN8Cl5
InChI Key: MLDQJTXFUGDVEO-UHFFFAOYSA-N

Names and Identifiers of 100012-18-8

CAS Number

100012-18-8

EC Number

608-209-4

IUPAC Name

4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide

InChI

InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)

InChIKey

MLDQJTXFUGDVEO-UHFFFAOYSA-N

Canonical SMILES

CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F

UNII

9ZOQ3TZI87

Physical and chemical properties of 100012-18-8

Boiling Point

523.3±50.0 °C at 760 mmHg

Decomposition

Dangerous products of decomposition: thermal ecomposition may produce toxic gases such as carbon monoxide, carbon dioxide, and nitrogen oxides. /Sorafenib tosylate/

Density

1.5±0.1 g/cm3

Exact Mass

464.086304

Flash Point

270.3±30.1 °C

Index of Refraction

1.626

LogP

3.8

Melting Point

205.6 °C

Molecular Formula

C44H36MnN8Cl5

Molecular Weight

909

Stability

Stable if stored as directed; avoid strong oxidizing agents. /Sorafenib tosylate/

Vapour density

4.11X10-14 mm Hg at 25 °C (est)

Vapour Pressure

0.0±1.4 mmHg at 25°C

Water Solubility

Soluble in water, 0.1M TRIS-HCl, pH 9.0 containing 1mM EDTA (>50 mg/ml), and PBS, pH 7.2 (4 mg/ml).

Safety Information of 100012-18-8

Pictograms

Signal Word

 Danger

Safety Data Sheet
Supports customized editing of SDS information and downloading in PDF documents.

Interaction Studies of 100012-18-8

Studies have demonstrated that sorafenib interacts with various cellular pathways:

  • Tyrosine Kinase Inhibition: Its primary mechanism involves inhibiting multiple receptor tyrosine kinases, which play crucial roles in cancer cell signaling and angiogenesis.
  • Drug Resistance Mechanisms: Research has highlighted noncoding RNAs' roles in mediating resistance to sorafenib, indicating complex interactions at the molecular level that can affect treatment efficacy.

Biological Activity of 100012-18-8

Sorafenib exhibits potent anti-cancer activity through multiple mechanisms:

  • Inhibition of Tumor Cell Proliferation: By blocking the Raf/MEK/ERK signaling pathway, sorafenib effectively inhibits cell proliferation and induces apoptosis in tumor cells.
  • Angiogenesis Inhibition: Sorafenib disrupts angiogenesis by inhibiting the autophosphorylation of receptor tyrosine kinases involved in endothelial cell signaling, particularly VEGFRs and PDGFRs.
  • Resistance Mechanisms: Despite its efficacy, resistance to sorafenib can develop through various mechanisms such as activation of alternative signaling pathways (e.g., PI3K/Akt) and upregulation of ATP-binding cassette transporters that expel the drug from cells.